deferasirox and Adenocarcinoma, Basal Cell
deferasirox has been researched along with Adenocarcinoma, Basal Cell in 2 studies
Research
Studies (2)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Assayag, F; Becette, V; Bièche, I; Bonin, F; Callens, C; Caly, M; Chateau-Joubert, S; de la Grange, P; Gentien, D; Lallemand, F; Marangoni, E; Rapinat, A; Schnitzler, A; Servely, JL; Tury, S; Vacher, S | 1 |
Bedford, MR; Ford, SJ; Iqbal, T; Pang, W; Tselepis, C; Tucker, O; Wood, A | 1 |
Other Studies
2 other study(ies) available for deferasirox and Adenocarcinoma, Basal Cell
Article | Year |
---|---|
The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carboplatin; Cell Proliferation; Cisplatin; Deferasirox; Doxorubicin; Drug Synergism; Humans; Iron; Iron Chelating Agents; MCF-7 Cells; Mice, Nude; NF-kappa B; Phosphatidylinositol 3-Kinase; Signal Transduction; Time Factors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |
A comparative study of the iron status of patients with oesophageal adenocarcinoma to determine suitability for a clinical trial of iron chelation therapy.
Topics: Adenocarcinoma; Aged; Anemia, Iron-Deficiency; Benzoates; Chelation Therapy; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deferasirox; Esophageal Neoplasms; Esophagectomy; Female; Ferritins; Hemoglobins; Humans; Iron; Iron Chelating Agents; Male; Patient Selection; Prospective Studies; Triazoles | 2014 |